News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Crucell N.V. (CRXL) Announces PER.C6 Licensing Agreement With Vascular Biogenics Ltd.


10/19/2005 5:13:10 PM

LEIDEN, The Netherlands, March 30, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that it has signed a PER.C6(R) research license agreement with Israeli biopharmaceutical company Vascular Biogenics Ltd. The non-exclusive agreement allows Vascular Biogenics to use the PER.C6(R) cell line for the preparation and evaluation of gene therapeutics based on adenoviral vectors.

Read at Prime Zone


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES